Search Within

Hematologic Malignancies Research

Formats
  1. Journal Article (1545)
  2. Meeting Abstract (1260)
  3. Review (76)
  4. Editorial (35)
  5. Book Section (32)
  6. Research Letter (26)
  7. Conference Paper (15)
  8. Correspondence (8)
  9. Guidelines (4)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3005)
  2. GSK Faculty (2450)
  3. Department of Medicine (2318)
  4. Hematologic Malignancies, Division of (2120)
  5. Sloan Kettering Institute Faculty (2052)
  6. Molecular Pharmacology and Chemistry Program Faculty (1632)

More Groups

People
  1. Michel Sadelain (586)
  2. David Scheinberg (502)
  3. Alexander Lesokhin (381)
  4. Carl Landgren (336)
  5. Renier Brentjens (286)
  6. Gabriela Chiosis (281)

More People

Years
  1. 2025 (64)
  2. 2024 (131)
  3. 2023 (175)
  4. 2022 (126)
  5. 2021 (154)
  6. 2020 (173)

More Years

Publications
  1. Blood (660)
  2. Cancer Research (117)
  3. Journal of Clinical Oncology (112)
  4. Clinical Lymphoma, Myeloma and Leukemia (84)
  5. Biology of Blood and Marrow Transplantation (80)
  6. Molecular Therapy (68)

More Publications

Publishers
  1. American Society of Hematology (700)
  2. Nature Publishing Group (375)
  3. Elsevier Inc. (291)
  4. American Association for Cancer Research (245)
  5. American Society of Clinical Oncology (116)
  6. Cell Press (116)

More Publishers

Results (3005)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pharmacologically controlling protein-protein interactions through epichaperomes for therapeutic vulnerability in cancer
    Journal Article

    Joshi, S.; Gomes, E. D.; Wang, T.; Corben, A.; Taldone, T.; Gandu, S.; Xu, C.; Sharma, S.; Buddaseth, S.; Yan, P.; more...
    Communications Biology (2021)

    Fulltext@MSK | Save
  • Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM)
    Meeting Abstract

    Bahlis, N. J.; Raje, N. S.; Costello, C.; Dholaria, B. R.; Solh, M. M.; Levy, M. Y.; Tomasson, M. H.; Dube, H.; Liu, F.; Liao, K. H.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Using mobile wearables to establish sleep bioprofiles in newly diagnosed multiple myeloma (MM) patients
    Meeting Abstract

    Hevroni, G.; Mastey, D.; Tavitian, E.; Derkach, A.; Salcedo, M.; Mailankody, S.; Hassoun, H.; Lesokhin, A. M.; Smith, E. L.; Hultcrantz, M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Daratumumab, carfilzomib, lenalidomide, & dexamethasone for relapsed/refractory myeloma with salvage autologous hematopoietic cell transplant: Interim analysis of the multicenter 2nd chance protocol
    Meeting Abstract

    Shah, G.; Bal, S.; Rodriguez, C.; Chhabra, S.; Bayer, R.; Costa, L.; Lambird, J.; Ferrer, C.; Parascondola, A.; Marcello, L.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Providing nutritional guidance for patients with plasma cell disorders - A missed opportunity for hematologists and oncologists?
    Meeting Abstract

    Sweeney, N.; Malik, M.; Jafri, M.; Derkach, A.; Chmielewski, C.; Adintori, P.; Mailankody, S.; Korde, N.; Tan, C.; Hassoun, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Sustained minimal residual disease negativity in multiple myeloma is impacted positively by stool butyrate and healthier plant forward diets
    Meeting Abstract

    Shah, U.; Derkach, A.; Adintori, P.; Cross, J.; Maclachlan, K.; Mailankody, S.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Tan, C.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • High quality neoantigens are immunoedited in long-term pancreatic cancer survivors
    Meeting Abstract

    Rojas, L. A.; Łuksza, M.; Sethna, Z. M.; Soares, K.; Leung, J.; Lihm, J.; Hoyos, D.; Dobrin, A.; Kappagantula, R.; Makohon-Moore, A.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • MagnetisMM-1 study of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients (pts) with relapsed or refractory multiple myeloma (MM)
    Meeting Abstract

    Dholaria, B.; Bahlis, N.; Raje, N.; Costello, C.; Solh, M.; Levy, M.; Tomasson, M.; Dube, H.; Damore, M.; Lon, H. K.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Dynamic variability in SHP-1 abundance determines natural killer cell responsiveness
    Journal Article

    Wu, Z.; Park, S.; Lau, C. M.; Zhong, Y.; Sheppard, S.; Sun, J. C.; Das, J.; Altan-Bonnet, G.; Hsu, K. C.
    Science Signaling (2021)

    Fulltext@MSK | Save
  • Fibroblast pyruvate carboxylase is required for collagen production in the tumour microenvironment
    Journal Article

    Schwörer , S.; Pavlova, N. N.; Cimino, F. V.; King, B.; Cai, X.; Sizemore, G. M.; Thompson, C. B.
    Nature Metabolism (2021)

    Fulltext@MSK | Save